Oral Azacitidine for the Treatment of Relapsed or Refractory T-cell Large Granular Lymphocytic Leukemia

Recruiting

Phase 1

Phase 2

Oral Azacitidine for the Treatment of Relapsed or Refractory T-cell Large Granular Lymphocytic LeukemiaOral Azacitidine for the Treatment of Relapsed or Refractory T-cell Large Granular Lymphocytic Leukemia

Sponsor:

Jonathan Brammer

Code:

NCT05141682

Conditions

T-Cell Large Granular Lymphocyte Leukemia

Eligibility Criteria

Sex: All

Age: 18+

Healthy Volunteers: Not accepted

Interventions

Oral Azacitidine

Study Details

Eligibility Criteria

Study Design

Interventions and Outcome Measures

Central Contacts and Locations

More Information

Trial information was received from ClinicalTrials.gov and was last updated on 2025-03-25. This information was provided to ClinicalTrials.gov by Jonathan Brammer on 2025-02-24.